Saturday, 31 October 2026European Markets

AERKOMM INC Stock Jumps 26% In 5 Days: What's Driving The Surge?

Loading stream...

(vianews) - investors have shown great enthusiasm over aerkomm inc's stock performance, as shares increased by 26.13% in just five sessions from trading at eur2.22 on thursday to hitting eur2.80 at 14:55 est on monday afternoon - part of an upward trend that also contributed to cac 40 index currently rising 0.14% to eur7,602.52.

about aerkomm inc

aerkomm inc. is an established provider of in-flight entertainment and connectivity (ifec) solutions in asia pacific region, offering airline passengers wi-fi, cellular services, movies, gaming, live tv and music on both built-in inflight entertainment systems as well as personal devices in flight. aerkomm also offers content management solutions as well as content ecommerce offerings with its comprehensive k++ solution ifec system. founded in 2013, aerkomm's headquarters are in fremont california where it has pioneered innovation within its industry. founded in 2013, aerkomm is at the forefront of revolutionizing in-flight entertainment industry with revolutionary services offered to both built-in inflight systems as well as passengers' personal devices in flight. founded in 2013, aerkomm has revolutionized inflight entertainment industry!

technical analysis

aerkomm inc's stock has experienced high volatility over the past week, registering an average intraday variance of 26.13% - this represents an exponential rise from its prior average volatility of 13.52% and was recorded as its highest amplitude in one week at 26.13%. even with all this volatility, aerkomm inc's stock is currently considered oversold according to the stochastic oscillator indicator. this tool detects overbought and oversold conditions in the market and readings of 20 or below indicate an oversold condition in aerkomm's case. importantly, investors should remember that simply because a stock may currently be undervalued does not equate to being an ideal time for acquisition. they should carefully consider factors like financial performance and industry trends when making investment decisions.

equity analysis

earnings per share (eps) measures the portion of a company's profits allocated to each outstanding share. aerkomm inc's trailing twelve month eps was eur-1.35; this negative figure indicates the company incurred losses amounting to eur1.35 per share over the past year and could indicate financial difficulties for aerkomm. investors should be wary of negative eps figures, which could signal that a company is performing poorly financially. when evaluating stocks as potential investments, other factors must also be taken into account, including revenue growth, industry trends and overall economic environment; simply considering negative eps numbers alone may not suffice in making an informed decision about investing or not in certain companies.

more news about aerkomm inc (akom.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com